Summary Following adjuvant therapy for breast cancer, some patients will die of this tumour while the remainder will die of other causes. Deaths from breast cancer tend to follow a lognormal distribution, while deaths from other causes can be approximated by national demographic data. By combining these two survival models, we have generated an age-specific method for estimating the 
In our treatment of patients with cancer, we cannot hope to prolong life forever. Even those patients who are cured of their tumour will eventually die from other causes. The best that we can hope for is to increase survival rate beyond the level that would have occurred without treatment. By this logic, it would seem reasonable to judge the relative effectiveness of treatment by comparing survival rates at a specific endpoint following diagnosis.
Indeed, such comparison is the express purpose of modern prospective, randomised clinical trials. Since these trials demand so much of patients and of society at large, we must perform our comparisons with the most appropriate statistical model. The current 'gold standard' for clinical trials includes a variety of non-parametric methods, such as the log rank test (Peto et al., 1976 and 1977) . These methods are cherished above all others because their derivations incorporate minimal assumptions. Such paucity of assumptions is achieved by excluding from the model those parameters that govern tumour-related survival -i.e., likelihood of cure and median tumour-related survival time among uncured patients.
It is important to note, however, that cancer treatment is fundamentally a parametric process: Effective therapy must increase rate of cure, increase time to death from tumour among uncured patients, or achieve a combination of these effects. Thus if we wish to measure precisely the long-term impact of treatment, we must consider the impact of therapy on cured fraction and median tumour-related survival time.
Unfortunately, the survival rate at a specific endpoint is not always an accurate measure of these two parameters. An initial advantage in survival rate at five years will vanish with progressive follow-up if the two treatment groups have the same cured fraction. An even more dramatic disparity between short-term and long-term follow-up is shown in Figure 1 , which compares two hypothetical treatment groups. That group with the longest median survival time has a higher initial survival rate, while that group with the largest cured fraction has higher long-term survival rate. Nonparametric analysis would distinguish the best long-term therapy only if performed after the curves cross at 10 years. Figure 1 represents a worst-case scenario, and such crossing of survival curves may be an unlikely event. We are aware of only one example where such a phenomenon has been observed in a clinical trial (Cuzick et al., 1987) . Nevertheless, non-parametric methods could lead to serious errors in the analysis of clinical trials: (i) The therapy we select based on short-term follow-up may enhance only survival time and thus offer no long-term survival benefit. (ii) Alternatively, we might conclude after limited follow-up that there is no difference among treatment groups, when in reality one therapy enhances cured fraction and thus offers a significant long-term advantage. (iii) When treatment groups differ substantially in their median survival times, the assumption of proportional hazards is violated, and this assumption is incorporated in many non-parametric methods (Peto et al., 1976 and 1977) .
Given both the ambiguity of survival rate at a specific endpoint and the limitations of non-parametric methods, we might be tempted to consider only the impact of therapy on cured fraction. Unfortunately, this approach also poses a number of problems: (i) The parametric methods used to estimate cured fraction are complex and have little power unless available follow-up extends beyond the median value for tumour-related survival time (Boag, 1949; Gamel et al., 1990 
(1) C = cured fraction, and
where D(s) is a function with unit integral that represents the distribution of time to death from breast cancer. Alternatively, for a log-based distribution, the range of integration for D(s) becomes s = -co to s = log t (Boag, 1949) .
A number of authors have shown that time to death from many cancers tends to follow a lognormal distribution (Boag, 1949; Mould & Boag, 1975; Mould et al., 1976; Gamel et al., 1990) . The most extensive study to date of breast cancer (Rutqvist et al., 1984) incorporated 14,731 patients, 5,252 of whom had stage 2 disease. Using this population, Rutvqist derived lognormal estimates of basic survival parameters, including cured fraction (C), mean (M) and standard deviation (S) of log survival time. For patients with stage 2 disease, these values were C= 0.27, M = 1.22, S = 1.04, with median survival time exp{M} = 3.4 years. Since these patients were managed in the era before adjuvant therapy, we assume that these parameters represent the baseline clinical course of 'untreated' patients with stage 2 disease. Using these parameters in the lognormal model, the tumour-related survival rate was 53% at 5 years, 38% at 10 years, and 33% at 15 years after diagnosis.
We simulated therapeutic impact by enhancing either cured fraction or mean log survival time to generate a specific increase in the survival rate at follow-up intervals of 5, 10, and 15 years. At each interval, we' used equation (1) 'Tumour-related survival rate of untreated patients is 53% at 5 years, 38% at 10 years, and 33% at 15 years. Percentages shown in this column represent absolute increases in the tumour-related survival rate produced at each follow-up interval by increasing either C (cured fraction) or M (mean log tumour-related survival time) as the result of hypothetical adjuvant therapy. .1n years.
Results Figure 1 shows two tumour-related survival curves which have the same value after ten years of follow-up, despite substantial differences in cured fraction. From this figure it is apparent that follow-up at 5 or 10 years is not a reliable index of long-term survival. Table I shows the differential impact on MSTAC of increases in cured fraction (C) versus increases in mean log tumour-related survival time (M). The first row represents MSTAC for patients that received no adjuvant treatment. For younger patients, survival rate increases at 5 and 10 years that are due to enhanced C yield greater increases in MSTAC than those increases that are due to enhanced M. For example, for 35 year old patients, a 20% increase in the survival rate from breast cancer at 5 years yields a 28 year increase in MSTAC if due to enhanced C, but only a 6 year increase if due to enhanced M. It is important to note that non-parametric survival methods cannot distinguish between these two mechanisms for enhancing survival rate. Figure 2 shows variations in values of MSTAC when the loglogit or Weibull functions are substituted for the lognormal function in the model of tumour-related survival. It is apparent from this figure that the function selected has relatively little impact on these values.
Discussion
As noted in the Introduction above, we rely primarily on controlled clinical trials to select the optimum adjuvant therapy for patients with stage 2 breast cancer. We generally make our selection within 5 to 10 years after treatment, using a non-parametric method to determine which group has the best survival rate. Hidden within this process, however, is an unspoken assumption: That treatment which yields the best short-term survival rate will also yield the best long-term clinical course. Unfortunately, we now have several reasons to call this assumption into question.
(1) An earlier study revealed that, with limited follow-up, an increase in cured fraction is more difficult to detect by the log rank test than a comparable increase in median tumour-related survival time (Gamel et al., 1993) .
(2) We cannot rely on differences in the survival rate at an early endpoint to determine which treatment yields the largest cured fraction (Figure 1 ). This is especially true for younger patients (Table I) . Such sensitivity is largely independent of the particular function selected to represent the tumour-related survival rate (Figure 2 ). Taking these findings in concert, we must conclude that the short-term survival rate is a limited measure of long-term clinical course. Fortunately, with increasing follow-up:
(1) The log rank test becomes progressively more sensitive to enhanced cured fraction and less sensitive to enhanced median tumour-related survival time (Gamel et al., 1993) . (2) Tumour-related survival rate becomes a more reliable index of cured fraction (Figure 1 ). (3) The long-term clinical impact of a specific increase in survival rate becomes less sensitive to cured fraction (Table I) .
Unfortunately, the clinical exigencies of adjuvant therapy argue for the shortest possible follow-up. Trials are very expensive, and we want to offer the best treatment to all patients as soon as possible. In seeking to resolve this dilemma, we should give careful consideration to two important issues:
Patient age
The findings shown in Table I suggest that older patients enjoy less benefit from therapy than younger patients. Furthermore, because of the greater likelihood of death from other causes, older patients provide less follow-up data with which to evaluate therapeutic effect.
Duration offollow-up We do not have sufficient evidence to justify a radical revision of the protocols for clinical trials. For the foreseeable future, we will continue using non-parametric methods to detect an early separation in survival curves. Nevertheless, these protocols could allow for a 'second look' at some predetermined time (e.g., 5 or 10 years) beyond the traditional 'first look'. Such a second look would demand relatively little additional expenditure -specifically, the money required to maintain follow-up surveillance for the additional time interval. Given the initial investment, and given the long-term costs of an erroneous early conclusion, such a cautionary measure would seem to justify the cost.
